KGREL tablets (cardiovascular)

1) Efficacy, effect

1. Improvement of atherosclerotic symptoms in adult patients with ischemic stroke, myocardial infarction, or peripheral arterial disease

2. Patients with acute coronary syndrome [unstable angina or non-Q wave myocardial infarction, who have received or will receive medical treatment or coronary intervention (PCI) (with or without stenting) and coronary artery bypass grafting (CABG) Improvement of atherosclerotic symptoms (death, myocardial infarction, stroke, or refractory ischemia due to cardiovascular disorders) in adult patients with [including]

3. Reduces the risk of atherothrombosis and thromboembolism, including stroke, in adult patients with atrial fibrillation who have one or more vascular risk factors, are not suitable for vitamin K antagonist (VKA) administration, and have a low risk of bleeding.

2) Usage, dosage

Clopidorogrel is administered orally at 75 mg once a day.

This drug can be administered regardless of food intake.

3) Packaging unit

30 tablets/bottle

4) Ingredients, content

5) Period of use

36 months from date of manufacture

6 ) Storage method

Airtight container, stored at room temperature (1∼30°C)